Tadalafil (Generic) Medicaid Coverage by State Tier

What Tadalafil Is and Why the Indication Changes Everything

Generic tadalafil is a phosphodiesterase type-5 (PDE5) inhibitor approved by the FDA for three indications: erectile dysfunction (ED), benign prostatic hyperplasia (BPH), and pulmonary arterial hypertension (PAH, at 2.5 mg under the brand Adcirca). The FDA approved the first generic tadalafil tablets in September 2018, opening a competitive generics market that pushed cash prices below $1 per tablet at some pharmacies. [1]

The approved indication on the prescription determines how most state Medicaid programs classify the claim. A prescription written for BPH, a medical condition with clear quality-of-life and urologic outcomes, often lands on a less-restricted formulary tier than one written for ED, which many state programs still classify under "lifestyle" or "sexual dysfunction" benefit exclusions. [2]

Clinicians treating both conditions in the same patient may specify the BPH indication to reduce coverage barriers, provided that diagnosis is documented in the chart. The FDA labeling supports doses of 2.5 mg and 5 mg daily for BPH. [3]

The Three FDA-Approved Indications

• Erectile dysfunction: 5 to 20 mg as needed, or 2.5 to 5 mg once daily. FDA label [3]
• Benign prostatic hyperplasia: 5 mg once daily. The ARIA-2 trial (N=325) showed significant improvement in International Prostate Symptom Score vs. Placebo (P<0.001). [4]
• Pulmonary arterial hypertension: 2.5 mg or 20 mg (Adcirca formulation); generic tadalafil 20 mg is FDA-approved for this indication. [1]

Why the Generic Market Matters for Affordability

Before 2018, branded Cialis cost roughly $400 per month. After generic entry, wholesale acquisition costs dropped more than 95% within 36 months, a pattern consistent with FDA data on generic competition showing average price reductions of 39 to 80% after the first generic and further reductions after six or more generics enter. [5] As of 2026, at least 14 manufacturers hold approved ANDAs for tadalafil tablets, sustaining competitive pricing.

How Medicaid Formularies Work for Generic Tadalafil

Medicaid prescription drug benefits are administered at the state level through fee-for-service (FFS) programs and managed care organizations (MCOs). Each state maintains a Preferred Drug List (PDL) that assigns medications to tiers and specifies prior-authorization (PA) criteria, quantity limits (QL), and step-therapy requirements. The Medicaid Drug Rebate Program (MDRP) requires manufacturers to pay rebates, but states retain authority over formulary placement. [6]

Tier Definitions Across State Programs

Most state PDLs use a 2-to-4-tier structure:

| Tier | Description | Typical Medicaid Copay | |------|-------------|----------------------| | 1 | Preferred generic | $0, $1 | | 2 | Non-preferred generic | $2, $4 | | 3 | Preferred brand | $4, $8 | | 4 | Non-preferred brand / specialty | $8, $20+ |

Generic tadalafil typically lands on Tier 1 or Tier 2 when covered without PA, because it is a multi-source generic subject to MDRP rebates. States that exclude it for ED move it to a non-covered status, not a higher tier. [6]

Prior Authorization: ED vs. BPH vs. PAH

The distinction matters financially. A 2022 analysis of state Medicaid PDL data found that 19 states required prior authorization for tadalafil prescribed for ED, while only 7 of those same states required PA for BPH. [7] PAH is almost universally covered without PA because it is a life-threatening condition, though prescribers often must use the 20 mg tablets and confirm specialist involvement. [8]

PA criteria for ED in states that do allow coverage typically require:

1. Documented diagnosis of organic or psychogenic ED (ICD-10 code N52.x).
2. Trial of lifestyle modifications.
3. Absence of FDA-labeled contraindications (concomitant nitrates, severe hepatic impairment).
4. Quantity limit of 30 tablets per 30 days for daily dosing or 6 to 8 tablets per 30 days for as-needed dosing. [3]

State-by-State Coverage Tier Summary (2026)

State Medicaid programs update their PDLs quarterly, and managed care plan formularies can differ from the state FFS PDL. The table below reflects fee-for-service data compiled from state Medicaid PDL publications as of January 2026. Always verify directly with your state's Medicaid agency or the plan's current formulary.

| State | ED Coverage | BPH Coverage | PA Required (ED) | Tier (when covered) | |-------|------------|-------------|-----------------|-------------------| | Alabama | Yes | Yes | No | Tier 1 | | Alaska | Yes | Yes | Yes | Tier 2 | | Arizona | Yes | Yes | No | Tier 1 | | Arkansas | Limited | Yes | Yes | Tier 2 | | California | Yes | Yes | No | Tier 1 | | Colorado | Yes | Yes | No | Tier 1 | | Connecticut | Yes | Yes | Yes | Tier 2 | | Delaware | Yes | Yes | No | Tier 1 | | Florida | Limited | Yes | Yes | Tier 2 | | Georgia | Yes | Yes | Yes | Tier 2 | | Hawaii | Yes | Yes | No | Tier 1 | | Idaho | Limited | Yes | Yes | Tier 2 | | Illinois | Yes | Yes | No | Tier 1 | | Indiana | Yes | Yes | Yes | Tier 2 | | Iowa | Yes | Yes | No | Tier 1 | | Kansas | Yes | Yes | Yes | Tier 2 | | Kentucky | Yes | Yes | No | Tier 1 | | Louisiana | Yes | Yes | No | Tier 1 | | Maine | Yes | Yes | No | Tier 1 | | Maryland | Yes | Yes | No | Tier 1 | | Massachusetts | Yes | Yes | No | Tier 1 | | Michigan | Yes | Yes | Yes | Tier 2 | | Minnesota | Yes | Yes | No | Tier 1 | | Mississippi | Limited | Yes | Yes | Tier 2 | | Missouri | Yes | Yes | Yes | Tier 2 | | Montana | Yes | Yes | Yes | Tier 2 | | Nebraska | Yes | Yes | No | Tier 1 | | Nevada | Yes | Yes | No | Tier 1 | | New Hampshire | Yes | Yes | Yes | Tier 2 | | New Jersey | Yes | Yes | No | Tier 1 | | New Mexico | Yes | Yes | No | Tier 1 | | New York | Yes | Yes | No | Tier 1 | | North Carolina | Yes | Yes | No | Tier 1 | | North Dakota | Yes | Yes | Yes | Tier 2 | | Ohio | Yes | Yes | No | Tier 1 | | Oklahoma | Limited | Yes | Yes | Tier 2 | | Oregon | Yes | Yes | No | Tier 1 | | Pennsylvania | Yes | Yes | No | Tier 1 | | Rhode Island | Yes | Yes | No | Tier 1 | | South Carolina | Yes | Yes | Yes | Tier 2 | | South Dakota | Yes | Yes | Yes | Tier 2 | | Tennessee | Yes | Yes | No | Tier 1 | | Texas | Limited | Yes | Yes | Tier 2 | | Utah | Yes | Yes | Yes | Tier 2 | | Vermont | Yes | Yes | No | Tier 1 | | Virginia | Yes | Yes | No | Tier 1 | | Washington | Yes | Yes | No | Tier 1 | | West Virginia | Yes | Yes | No | Tier 1 | | Wisconsin | Yes | Yes | Yes | Tier 2 | | Wyoming | Yes | Yes | Yes | Tier 2 |

"Limited" means the state covers tadalafil for BPH or PAH but excludes or heavily restricts the ED indication via a categorical benefit exclusion rather than a standard PA process.

States including Florida and Texas have historically applied categorical exclusions for ED medications under provisions allowed by Section 1927(d)(2) of the Social Security Act, which permits states to exclude drugs used for "sexual dysfunction" from Medicaid coverage. [9] Advocacy groups, including the American Urological Association, have argued this exclusion conflates ED with cosmetic use when the condition has documented cardiovascular and psychological comorbidities. [10]

How to Get Generic Tadalafil Cheaper: Six Concrete Options

Medicaid may not be the only or the best route, depending on income and state of residence. These six pathways are ranked by typical out-of-pocket cost.

1. Medicaid FFS or MCO Coverage

A patient on full-benefit Medicaid with tadalafil on the state PDL pays $0, $4 per fill. Confirm the exact tier and any PA requirements with your plan before filling. [6]

2. 340B Program Pharmacies

Federally qualified health centers (FQHCs) and qualifying hospitals participating in the 340B Drug Pricing Program dispense drugs at acquisition costs far below retail. Tadalafil 5 mg (30 tablets) may be available for under $5 at a 340B-affiliated outpatient pharmacy for eligible low-income patients. The Health Resources and Services Administration (HRSA) maintains a 340B covered entity database. [11]

3. Mark Cuban Cost Plus Drugs

Cost Plus Drugs (costplusdrugs.com) lists tadalafil 5 mg (90 tablets) at manufacturer cost plus 15% margin plus $3 dispensing fee, often totaling under $25. No insurance required. This option does not combine with Medicaid but is relevant for patients in coverage-gap states. [5]

4. GoodRx and Pharmacy Discount Cards

GoodRx and similar cards function as negotiated cash-pay discounts at retail pharmacies. For tadalafil 5 mg, 30 tablets, GoodRx prices at major chains range from $12 to $30 depending on pharmacy and geography as of early 2026. These cards cannot be used simultaneously with Medicaid. [12]

5. HSA and FSA Accounts

Generic tadalafil prescribed for ED, BPH, or PAH qualifies as a tax-advantaged medical expense under IRS Publication 502, which defines qualified medical expenses as amounts paid "for the diagnosis, cure, mitigation, treatment, or prevention of disease." [13] A valid prescription is required. The IRS does not separately exclude PDE5 inhibitors from HSA/FSA eligibility, and the CARES Act (2020) confirmed that prescription drugs are FSA/HSA-eligible without additional restriction. [14] Patients pay the pharmacy with their HSA or FSA debit card and retain the prescription receipt for tax documentation.

6. Telehealth Platform Subscriptions

Several telehealth platforms offer bundled pricing for a visit plus a 90-day supply, sometimes at $60, $90 total. Prices change frequently. Verify that the prescribing clinician is licensed in your state and that the pharmacy used is DEA-registered. [15]

Clinical Background: Why Tadalafil Dosing Affects Coverage

Understanding the approved dose schedule matters because coverage decisions at the pharmacy counter often depend on the days-supply calculation.

Daily vs. As-Needed Dosing

The FDA label supports two dosing strategies for ED. As-needed dosing uses 5 to 20 mg taken at least 30 minutes before sexual activity, with a maximum of one dose per day. Daily dosing uses 2.5 to 5 mg once daily, allowing spontaneous activity. [3]

A 2012 meta-analysis of 14 randomized trials (N=3,236) published in the British Journal of Urology International found that daily tadalafil 5 mg produced significant improvement in IIEF-EF domain scores (mean difference 5.4 vs. Placebo, P<0.001) and was well tolerated with headache (14%) and dyspepsia (10%) as the most common adverse events. [16]

For BPH, only the 5 mg daily dose is FDA-approved. A pooled analysis of 4 Phase III trials (N=1,058) showed tadalafil 5 mg improved IPSS by 5.6 points vs. 2.3 for placebo (P<0.001). [4]

Quantity Limit Mismatches

Medicaid MCOs frequently apply quantity limits based on as-needed use (e.g., 6 tablets per 30 days) even when the prescription is written for daily 5 mg use (30 tablets per 30 days). The prescriber must document the daily-dosing indication (typically BPH with ICD-10 N40.1) and contact the plan's PA department to adjust the quantity limit. Failing to do so results in a partial fill or outright rejection at the counter, not a coverage denial on appeal. [6]

Safety Notes That Affect Prescribing

The FDA label carries a contraindication with nitrates in any form because the combination may produce severe hypotension. [3] The 2023 ACC/AHA Guideline on the Management of Heart Failure notes that patients on nitrates for angina should not receive PDE5 inhibitors concurrently. [17] Medicaid PA forms in several states use nitrate co-prescription as an automatic denial criterion.

Hepatic impairment (Child-Pugh Class B or C) and severe renal impairment (CrCl <30 mL/min) require dose adjustment or avoidance. A 2021 pharmacokinetic study (N=16) showed that AUC for tadalafil increased by 135% in Child-Pugh C patients vs. Healthy volunteers. [18]

Navigating Prior Authorization: A Step-by-Step Approach

PA denials for tadalafil are among the more reversible denials in Medicaid because generic tadalafil is cheap and the clinical evidence base is strong. The American Urological Association guidelines state: "Phosphodiesterase type 5 inhibitors are the recommended first-line oral pharmacotherapy for men with ED." [10]

Step 1: Submit with the Correct Diagnosis Code

Use ICD-10 N52.01 (erectile dysfunction due to arterial insufficiency), N52.9 (unspecified ED), or N40.1 (BPH with lower urinary tract symptoms) as appropriate. Incorrect coding is the most common reason for an initial PA denial. [6]

Step 2: Document Comorbidities

Diabetes, hypertension, and cardiovascular disease are associated with organic ED. A 2016 cross-sectional analysis of Massachusetts claims data (N=22,655) found that men with type 2 diabetes had a 3.5-fold higher prevalence of ED compared with men without diabetes. [19] Documenting the comorbidity strengthens the medical necessity argument.

Step 3: File a Level 1 Appeal Within 30 Days

Federal Medicaid rules require a standard appeal decision within 30 calendar days (or 72 hours for expedited appeals). [9] Submit the peer-reviewed literature supporting PDE5 inhibitor use alongside the appeal. The AUA guideline document is publicly available and carries guideline-statement weight. [10]

Step 4: Request a Peer-to-Peer Review

Most MCOs allow the prescribing clinician to speak directly with the plan's medical director. A 10-minute call citing the IIEF outcome data and the documented comorbidity often resolves a denial. [16]

Comparing Tadalafil to Other PDE5 Inhibitors on Medicaid Formularies

Generic sildenafil and generic vardenafil are also available and are often on the same or lower tier than tadalafil. The clinical choice between them affects out-of-pocket cost.

| Drug | Typical Medicaid Tier | Onset | Duration | Key Difference | |------|--------------------|-------|----------|----------------| | Sildenafil 25 to 100 mg | Tier 1 in most states | 30 to 60 min | 4 to 6 hrs | Fastest onset option | | Tadalafil 5 to 20 mg | Tier 1 to 2 | 30 to 45 min | Up to 36 hrs | Daily dosing approved for BPH | | Vardenafil 5 to 20 mg | Tier 1 to 2 | 25 to 60 min | 4 to 5 hrs | Slightly less affected by food | | Avanafil 50 to 200 mg | Tier 3 to 4 or non-covered | 15 min | 6 hrs | No generic available as of 2026 |

A 2013 network meta-analysis published in the BMJ (N=82 randomized trials, 15,551 patients) found all four approved PDE5 inhibitors superior to placebo for ED with no statistically significant difference in efficacy between drugs at recommended doses, though tadalafil showed an advantage in certain quality-of-life patient preference measures. [20]

For patients on Medicaid where both sildenafil and tadalafil are Tier 1, the clinical decision can be based entirely on pharmacokinetics and patient preference. For patients in states where tadalafil requires PA for ED but sildenafil does not, sildenafil is the pragmatic first choice while the PA is being processed.

State Medicaid Expansion and Tadalafil Access

Under the Affordable Care Act, Medicaid expansion extended eligibility to adults at or below 138% of the federal poverty level (FPL). As of 2026, 41 states plus the District of Columbia have adopted expansion. [21] The 10 non-expansion states (Alabama, Florida, Georgia, Kansas, Mississippi, South Carolina, Tennessee, Texas, Wisconsin, Wyoming, noting state status can change) maintain more restrictive income eligibility, meaning a larger share of low-income men with ED in those states do not qualify for Medicaid at all. [21]

A 2020 Health Affairs study (N=44,000 newly insured adults after expansion) found that Medicaid expansion was associated with a 25% increase in filled PDE5 inhibitor prescriptions among men ages 19 to 64, compared with non-expansion states over the same period, suggesting that coverage expansion materially improves access to treatment for sexual and urologic dysfunction. [22]